UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

The New England journal of medicine, 2006-06, Vol.354 (24), p.2542-2551

2006

Volltextzugriff (PDF)

Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Journal of clinical oncology, 2008-06, Vol.26 (16), p.2674-2682

2008

Volltextzugriff (PDF)

Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint

Contemporary clinical trials, 2011-01, Vol.32 (1), p.99-107

2011

Volltextzugriff (PDF)

Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial

European urology, 2013-12, Vol.64 (6), p.994-1002

2013

Volltextzugriff (PDF)

Prognostic value of waterfall plots with the addition of nontarget lesion data

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.11082-11082

2013

Volltextzugriff (PDF)

A rank-based randomized phase II design when the phase III design is based on overall survival (OS)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.6597-6597

2014

Volltextzugriff (PDF)

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients

Cancer chemotherapy and pharmacology, 2012-06, Vol.69 (6), p.1507-1518

2012

Volltextzugriff (PDF)

Robustness Properties of the Pitman-Morgan Test

Communications in statistics. Theory and methods, 2003-01, Vol.32 (9), p.1801-1816

2003

Volltextzugriff (PDF)

Letter to the Editor re Yu and Holmgren

Contemporary clinical trials, 2007-09, Vol.28 (5), p.674-674

2007

Volltextzugriff (PDF)

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Clinical cancer research, 2012-11, Vol.18 (22), p.6364-6372

2012

Volltextzugriff (PDF)

Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials

Contemporary clinical trials, 2007-09, Vol.28 (5), p.674-674

2007

Volltextzugriff (PDF)

University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion)

Clinical trials (London, England), 2015-08, Vol.12 (4), p.323-332

2015

Volltextzugriff (PDF)

Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): Implications for randomized phase II study design

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.2543-2543

2012

Volltextzugriff (PDF)

University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (afternoon panel discussion session)

Clinical trials (London, England), 2015-08, Vol.12 (4), p.365-373

2015

Volltextzugriff (PDF)

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma

Cancer chemotherapy and pharmacology, 2012, Vol.69 (1), p.281-287

2012

Volltextzugriff (PDF)

An Efficient Algorithm to Determine the Optimal Two-Stage Randomized Multinomial Designs in Oncology Clinical Trials

Journal of biopharmaceutical statistics, 2011-01, Vol.21 (1), p.56-65

2011

Volltextzugriff (PDF)

University of Pennsylvania 5th annual conference on statistical issues in clinical trials: Emerging statistical issues in biomarker validation (Morning Session)

Clinical trials (London, England), 2013-10, Vol.10 (5), p.680-689

2013

Volltextzugriff (PDF)

Cyclosporine as maintenance therapy in patients with severe psoriasis

Journal of the American Academy of Dermatology, 1997-03, Vol.36 (3), p.423-432

1997

Volltextzugriff (PDF)

Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma. A veterans administration lung cancer group study

Cancer, 1982-08, Vol.50 (4), p.646-651

1982

Volltextzugriff (PDF)

Preliminary report of a cooperative randomized study for the treatment of localized small cell lung carcinomat

International journal of radiation oncology, biology, physics, 1979, Vol.5 (9), p.1445-1447

1979

Volltextzugriff (PDF)

Clinical and Magnetic Resonance Imaging Changes Correlate in a Clinical Trial Monitoring Cyclosporine Therapy for Multiple Sclerosis

Journal of neuroimaging, 1997-01, Vol.7 (1), p.1-7

1997

Volltextzugriff (PDF)

A Review of: " Controversial Statistical Issues in Clinical Trials , by S.-C. Chow": Boca Raton, FL: Chapman & Hall/CRC, 2011, ISBN 978-1-4398-4961-3, xix + 590 pp., $99.95

Journal of Biopharmaceutical Statistics, 2012, Vol.22 (5), p.1088-1096

Mietlowski, William

2012

Volltextzugriff (PDF)

A Review of: " Modeling Survival Data Using Frailty Models , by D. D. Hanagal": Boca Raton, FL: Chapman & Hall/CRC, 2011, ISBN 978-1-4398-3667-5, xix + 314 pp., $89.95

Journal of Biopharmaceutical Statistics, 2012, Vol.22 (2), p.420-423

Mietlowski, William

2012

Volltextzugriff (PDF)

A Review of: "Frailty Models in Survival Analysis, by A. Wienke": Boca Raton, FL: Chapman and Hall/CRC, 2011, ISBN 978-1-4200-7388-1, xxi + 301 pp., $99.95

Journal of Biopharmaceutical Statistics, 2011, Vol.21 (4), p.860-862

Mietlowski, William

2011

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint

Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial

Prognostic value of waterfall plots with the addition of nontarget lesion data

A rank-based randomized phase II design when the phase III design is based on overall survival (OS)

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients

Robustness Properties of the Pitman-Morgan Test

Letter to the Editor re Yu and Holmgren

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials

University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion)

Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): Implications for randomized phase II study design

University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (afternoon panel discussion session)

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma

An Efficient Algorithm to Determine the Optimal Two-Stage Randomized Multinomial Designs in Oncology Clinical Trials

University of Pennsylvania 5th annual conference on statistical issues in clinical trials: Emerging statistical issues in biomarker validation (Morning Session)

Cyclosporine as maintenance therapy in patients with severe psoriasis

Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma. A veterans administration lung cancer group study

Preliminary report of a cooperative randomized study for the treatment of localized small cell lung carcinomat

Clinical and Magnetic Resonance Imaging Changes Correlate in a Clinical Trial Monitoring Cyclosporine Therapy for Multiple Sclerosis

A Review of: " Controversial Statistical Issues in Clinical Trials , by S.-C. Chow": Boca Raton, FL: Chapman & Hall/CRC, 2011, ISBN 978-1-4398-4961-3, xix + 590 pp., $99.95

A Review of: " Modeling Survival Data Using Frailty Models , by D. D. Hanagal": Boca Raton, FL: Chapman & Hall/CRC, 2011, ISBN 978-1-4398-3667-5, xix + 314 pp., $89.95

A Review of: "Frailty Models in Survival Analysis, by A. Wienke": Boca Raton, FL: Chapman and Hall/CRC, 2011, ISBN 978-1-4200-7388-1, xxi + 301 pp., $99.95

Suchergebnisse filtern